Zimmer Biomet Q2 adjusted EPS $2.01 beats; revenue +5.6% CC; full-year guidance reaffirmed

ZIMMER BIOMET HOLDINGS, INC.

2024-Q2 EPS reported $2.01 revenue$3,831,200,000

Q2 net sales $1.942B (+5.6% constant currency); diluted EPS $1.18 GAAP, $2.01 adjusted, exceeding expectations.
Net earnings $242.8M GAAP; adjusted net earnings $415.0M.
FY 2024 reported revenue guidance lowered to 4.0%-5.0% on FX; CC revenue growth 5.0%-6.0% and adjusted EPS $8.00-$8.15 reaffirmed.
Signed definitive agreement to acquire OrthoGrid Systems (AI hip guidance); also entered THINK Surgical and CBRE partnerships.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.